Harrow price target lowered to $58 from $65 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Harrow (HROW) to $58 from $65 and keeps a Buy rating on the shares. The firm is lowering its estimates slightly for Q4 and 2025 after reviewing Q4 script data in great detail. Lowered estimates are entirely driven by Triesence, as strong Iheezo demand drives Craig-Hallum’s estimates for the drug higher. Based on script data, the firm believes Triesence came in below its previously modeled $5.9M in the quarter.